Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more

Recent & Breaking News (NDAQ:SAGE)

SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

GlobeNewswire August 6, 2015

SAGE Therapeutics to Present at the Canaccord Genuity 35th Annual Growth Conference

GlobeNewswire August 5, 2015

SAGE Therapeutics, Inc. (Nasdaq: SAGE) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire July 8, 2015

SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression

GlobeNewswire June 9, 2015

SAGE Therapeutics to Participate in the Goldman Sachs 36th Annual Global Healthcare Conference

GlobeNewswire June 3, 2015

SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results

GlobeNewswire May 14, 2015

SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus

GlobeNewswire May 14, 2015

SAGE Therapeutics to Present at UBS Global Healthcare Conference

GlobeNewswire May 12, 2015

SAGE Therapeutics to Report First Quarter 2015 Financial Results on Thursday, May 14

GlobeNewswire May 7, 2015

SAGE Therapeutics Announces Closing of $138 Million Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

GlobeNewswire April 21, 2015

SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus

GlobeNewswire April 20, 2015

SAGE Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire April 14, 2015

SAGE Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire April 13, 2015

SAGE Therapeutics Announces Presentations at Upcoming Scientific Conferences

GlobeNewswire April 9, 2015

SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA and Planned Initiation of SAGE-547 Global Phase 3 Trial in Mid-2015

GlobeNewswire April 2, 2015

SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results

GlobeNewswire February 27, 2015

SAGE Therapeutics Appoints New Vice Presidents to Lead Key Organizational Functions

GlobeNewswire February 13, 2015

SAGE Therapeutics Announces Participation in February Conferences

GlobeNewswire January 28, 2015

SAGE Therapeutics Initiates Phase 2a Trial of SAGE-547 in Postpartum Depression

GlobeNewswire January 12, 2015

SAGE Therapeutics Reports Updated Data From Ongoing Clinical Trial and Emergency Use Program of SAGE-547 in Patients With Super-Refractory Status Epilepticus

GlobeNewswire January 9, 2015